Biosimilars, innovators and generic drugs
The first marketing authorization for a biosimilar was for a recombinant protein approved by the European Medicines Agency (EMA) in 2006. From this date biosimilars use has grown exponentially. In fact, from 30% to 50% of new drugs approved in Europe are estimated to be biosimilars. Health professionals must contribute to terms as biological, biosimilar…
